Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15425997 | 0.85 | ALDH1A1 (0.45) | SMN1; SMN2NPSR1TP53ALDH1A1KDM4E | |
| SCHEMBL395847 | 0.81 | KDM4E (0.62) | MTNR1AMTNR1BABCG2ALDH1A1KDM4E | |
| SCHEMBL31518169 | 0.80 | NR4A2 (0.59) | MTNR1AMTNR1BABCG2ALDH1A1KDM4E | |
| SCHEMBL12700469 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2NPSR1TP53GAAALDH1A1 | |
| SCHEMBL12611200 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2NPSR1TP53GAAALDH1A1 | |
| SCHEMBL3041131 | 0.80 | KMT2A (0.51) | SMN1; SMN2NPSR1TP53MTNR1AMTNR1B | |
| SCHEMBL3052938 | 0.78 | TP53 (0.48) | SMN1; SMN2NPSR1TP53MTNR1AMTNR1B | |
| SCHEMBL396665 | 0.76 | CLEC4M (0.57) | MTNR1AMTNR1BALDH1A1KDM4EHTR2A | |
| SCHEMBL1562284 | 0.74 | TUBB1 (0.62) | TUBB1 | |
| SCHEMBL7359725 | 0.74 | KDM4E (0.55) | MTNR1AMTNR1BALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
| WO-2012127214-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012127214-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | NOX4, NOX1, CYBB | SMN1; SMN2 2870/4885NPSR1 1680/4885TP53 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.